IP Library Patent Application 13788761
Patent Application
App. No. 13/788,761

Histatin for Corneal Wound Healing and Ocular Surface Disease

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/788,761
Abstract

Histatins may be used for corneal wound healing and as a treatment for ocular surface disease in humans and other animals. For example, histatins could be included in eye drops, eye gels, ointment, glue, or embedded in (polymer) contact lenses.

Claims (45)

1 . A method of treating corneal wounds, comprising the step of administering a therapeutic amount of at least a peptide fragment of at least one histatin at a site of a corneal wound.

2 . The method of claim 1 , wherein the histatin is administered using eye drops, gels, or ointments including histatin.

3 . The method of claim 1 , wherein the histatin is administered using tissue glue.

4 . The method of claim 1 , wherein the histatin is continually administered by incorporating histatin into a contact lens worn by a patient.

5 . The method of claim 1 , wherein humans are treated by the method.

6 . The method of claim 1 , wherein a histatin concentration is between approximately 0.1 μg/ml and approximately 1000 mg/ml.

7 . The method of claim 6 , wherein a histatin concentration is between approximately 0.1 μg/ml and 10 μg/ml.

8 . The method of claim 1 , wherein the step is repeated at least one time a day for a plurality of days.

9 . The method of claim 1 , wherein the step is repeated chronically at least one time a day.

10 . The method of claim 1 , wherein the step is repeated up to hourly for a plurality of days.

11 . The method of claim 1 , wherein the step is repeated at least two times a day for a plurality of days.

12 . The method of claim 1 , wherein the step is repeated at least three times a day for a plurality of days.

13 . The method of claim 1 , wherein the step is repeated three times a day for seven days.

14 . The method of claim 1 , wherein the step is repeated four times a day for five days.

15 . The method of claim 1 , wherein the therapeutic amount of histatin accelerates wound healing compared to corneal wounds not treated with histatin.

16 . The method of claim 1 , wherein the histatin comprises an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 1; SEQ. ID. NO. 2; SEQ. ID. NO. 3; SEQ. ID. NO. 4; SEQ. ID. NO. 5; SEQ. ID. NO. 6; SEQ. ID. NO. 7; SEQ. ID. NO. 8; SEQ. ID. NO. 9; SEQ. ID. NO. 10; SEQ. ID. NO. 11; SEQ. ID. NO. 12; SEQ. ID. NO. 13; SEQ. ID. NO. 14; SEQ. ID. NO. 15; SEQ. ID. NO. 16; SEQ. ID. NO. 17; SEQ. ID. NO. 18; SEQ. ID. NO. 19; SEQ. ID. NO. 20; SEQ. ID. NO. 21; SEQ. ID. NO. 22; SEQ. ID. NO. 23; SEQ. ID. NO. 24; SEQ. ID. NO. 25; SEQ. ID. NO. 26; SEQ. ID. NO. 27; SEQ. ID. NO. 28; SEQ. ID. NO. 29; SEQ. ID. NO. 30; SEQ. ID. NO. 31; SEQ. ID. NO. 32; SEQ. ID. NO. 33; and any combination of SEQ. ID. NO. 1 through SEQ. ID. NO. 33.

17 . The method according to claim 1 , wherein the histatin comprises a peptide comprising 8 to 44 amino acids.

18 . The method according to claim 1 , wherein the histatin includes an L peptide.

19 . The method according to claim 1 , wherein the histatin includes a cyclic peptide.

20 . The method of claim 1 , wherein the histatin is selected from the group consisting of:

a) at least a peptide fragment of histatin 1;

b) at least a peptide fragment of histatin 2;

c) at least a peptide fragment of histatin 5; and

d) any combination of a) through c).

21 . The method of claim 1 , wherein the histatin comprises:

a) at least a peptide fragment of histatin 1, at least a peptide fragment of histatin 2 or a combination of at least a peptide fragment of histatin 1 and at least a peptide fragment of histatin 2; and

b) at least a peptide fragment of histatin 5.

22 . The method of claim 21 , wherein the peptide fragment of histatin 5 is selected from the group consisting of SEQ. ID. NO. 30 and SEQ. ID. NO. 31.

23 . The method of claim 21 , wherein the peptide fragments of histatin 1 or histatin 2 are selected from the group consisting of SEQ. ID. NO. 4; SEQ. ID. NO. 5; SEQ. ID. NO. 8; SEQ. ID. NO. 9; SEQ. ID. NO. 13; SEQ. ID. NO. 29; and SEQ. ID. NO.

24 . The method of claim 1 , wherein the histatin is selected from the group consisting of:

a) histatin 1;

b) histatin 2;

c) histatin 5; and

d) any combination of a) through c).

25 . The method of claim 1 , wherein the histatin comprises:

a) histatin 1, histatin 2 or a combination of histatin 1 and histatin 2; and

b) histatin 5.

26 . The method of claim 25 , wherein the histatin comprises an amino acid sequence of histatin 5 selected from the group consisting of SEQ. ID. NO. 30 and SEQ. ID. NO. 31.

27 . The method of claim 25 , wherein the histatin comprises an amino acid sequence of histatin 1 or histatin 2 selected from the group consisting of SEQ. ID. NO. 4; SEQ. ID. NO. 5; SEQ. ID. NO. 8; SEQ. ID. NO. 9; SEQ. ID. NO. 13; SEQ. ID. NO. 29;

and SEQ. ID. NO. 33.

28 . The method of claim 1 , wherein the histatin comprises at least a first histatin and a second histatin, wherein:

a) the first histatin is selected from the group consisting of: i) at least a peptide fragment of histatin 1 and ii) at least a peptide fragment of histatin 2; and

b) the second histatin comprises at least a peptide fragment of histatin 5.

29 . The method of claim 28 , wherein the second histatin comprises an amino acid sequence selected from the group consisting of SEQ. ID. NO. 30 and SEQ. ID. NO. 31.

30 . The method of claim 28 , wherein the first histatin comprises an amino acid sequence selected from the group consisting of SEQ. ID. NO. 4; SEQ. ID. NO. 5; SEQ. ID. NO. 8; SEQ. ID. NO. 9; SEQ. ID. NO. 13; SEQ. ID. NO. 29; and SEQ. ID. NO. 33 .

Assignments (6)
RELEASE OF SECURITY INTEREST REEL 066839, FRAME 0679 Recorded Dec 31, 2025
From: LSP 6 HOLDING C.V., AS COLLATERAL AGENT
To: VISUS THERAPEUTICS, INC.
Reel/Frame 074145/0450 →
SECURITY INTEREST Recorded Mar 20, 2024
From: VISUS THERAPEUTICS, INC.
To: LSP 6 HOLDING C.V., AS COLLATERAL AGENT
Reel/Frame 066839/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2020
From: RAPID PATHOGEN SCREENING, INC.
To: VISUS THERAPEUTICS, INC.
Reel/Frame 052732/0296 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2018
From: ROS ACQUISITION OFFSHORE LP
To: RAPID PATHOGEN SCREENING, INC.
Reel/Frame 047834/0367 →
SECURITY INTEREST Recorded Oct 10, 2014
From: RAPID PATHOGEN SCREENING, INC.
To: ROS ACQUISITION OFFSHORE LP
Reel/Frame 033929/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2013
From: SAMBURSKY, ROBERT P.; VANDINE, ROBERT W.; CONDON, PETER
To: RAPID PATHOGEN SCREENING, INC.
Reel/Frame 029974/0041 →